Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Comorbidity and thirty-day hospital readmission odds in chronic obstructive pulmonary disease: a comparison of the Charlson and Elixhauser comorbidity indices.

Buhr RG, Jackson NJ, Kominski GF, Dubinett SM, Ong MK, Mangione CM.

BMC Health Serv Res. 2019 Oct 15;19(1):701. doi: 10.1186/s12913-019-4549-4.

2.

Gene Expression Alterations in the Bronchial Epithelium of e-Cigarette Users.

Corbett SE, Nitzberg M, Moses E, Kleerup E, Wang T, Perdomo C, Perdomo C, Liu G, Xiao X, Liu H, Elashoff DA, Brooks DR, O'Connor GT, Dubinett SM, Spira A, Lenburg ME.

Chest. 2019 Oct;156(4):764-773. doi: 10.1016/j.chest.2019.05.022. Epub 2019 Jun 22.

PMID:
31233743
3.

The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.

Krysan K, Tran LM, Grimes BS, Fishbein GA, Seki A, Gardner BK, Walser TC, Salehi-Rad R, Yanagawa J, Lee JM, Sharma S, Aberle DR, Spira AE, Elashoff DA, Wallace WD, Fishbein MC, Dubinett SM.

Cancer Res. 2019 Oct 1;79(19):5022-5033. doi: 10.1158/0008-5472.CAN-19-0153. Epub 2019 May 29.

PMID:
31142513
4.

Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions.

Beane JE, Mazzilli SA, Campbell JD, Duclos G, Krysan K, Moy C, Perdomo C, Schaffer M, Liu G, Zhang S, Liu H, Vick J, Dhillon SS, Platero SJ, Dubinett SM, Stevenson C, Reid ME, Lenburg ME, Spira AE.

Nat Commun. 2019 Apr 23;10(1):1856. doi: 10.1038/s41467-019-09834-2.

5.

Understanding the mechanisms of immune-evasion by lung cancer in the context of chronic inflammation in emphysema.

Salehi-Rad R, Dubinett SM.

J Thorac Dis. 2019 Feb;11(2):382-385. doi: 10.21037/jtd.2019.01.22. No abstract available.

6.

Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma.

Scafoglio CR, Villegas B, Abdelhady G, Bailey ST, Liu J, Shirali AS, Wallace WD, Magyar CE, Grogan TR, Elashoff D, Walser T, Yanagawa J, Aberle DR, Barrio JR, Dubinett SM, Shackelford DB.

Sci Transl Med. 2018 Nov 14;10(467). pii: eaat5933. doi: 10.1126/scitranslmed.aat5933.

7.

Functional profiling of circulating tumor cells with an integrated vortex capture and single-cell protease activity assay.

Dhar M, Lam JN, Walser T, Dubinett SM, Rettig MB, Di Carlo D.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):9986-9991. doi: 10.1073/pnas.1803884115. Epub 2018 Sep 17.

8.

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.

Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ.

Lung Cancer. 2018 Sep;123:91-98. doi: 10.1016/j.lungcan.2018.06.013. Epub 2018 Jun 22.

9.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS.

J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.

10.

The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma.

Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Braas D, Go J, Graeber TG, Parlati F, Demo S, Li R, Walser TC, Gricowski M, Shuman R, Ibarra J, Fridman D, Phelps ME, Badran K, St John M, Bernthal NM, Federman N, Yanagawa J, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB.

Cancer Cell. 2018 May 14;33(5):905-921.e5. doi: 10.1016/j.ccell.2018.04.002.

11.

Understanding the Hurdles in Lung Cancer Immunotherapy in the Context of Chronic Obstructive Pulmonary Disease.

Salehi-Rad R, Dubinett SM.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):835-837. doi: 10.1164/rccm.201803-0523ED. No abstract available.

PMID:
29589957
12.

Summarizing performance for genome scale measurement of miRNA: reference samples and metrics.

Pine PS, Lund SP, Parsons JR, Vang LK, Mahabal AA, Cinquini L, Kelly SC, Kincaid H, Crichton DJ, Spira A, Liu G, Gower AC, Pass HI, Goparaju C, Dubinett SM, Krysan K, Stass SA, Kukuruga D, Van Keuren-Jensen K, Courtright-Lim A, Thompson KL, Rosenzweig BA, Sorbara L, Srivastava S, Salit ML.

BMC Genomics. 2018 Mar 6;19(1):180. doi: 10.1186/s12864-018-4496-1.

13.

Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells.

Walser TC, Jing Z, Tran LM, Lin YQ, Yakobian N, Wang G, Krysan K, Zhu LX, Sharma S, Lee MH, Belperio JA, Ooi AT, Gomperts BN, Shay JW, Larsen JE, Minna JD, Hong LS, Fishbein MC, Dubinett SM.

Cancer Res. 2018 Apr 15;78(8):1986-1999. doi: 10.1158/0008-5472.CAN-17-0315. Epub 2018 Feb 5.

14.

Impact of Chronic Obstructive Pulmonary Disease on Immune-based Treatment for Lung Cancer. Moving toward Disease Interception.

Dubinett SM, Spira AE.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):278-280. doi: 10.1164/rccm.201710-2065ED. No abstract available.

PMID:
29072842
15.

Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.

Sivakumar S, Lucas FAS, McDowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, Dubinett SM, Spira AE, Fowler J, Hawk ET, Wistuba II, Scheet P, Kadara H.

Cancer Res. 2017 Nov 15;77(22):6119-6130. doi: 10.1158/0008-5472.CAN-17-1605. Epub 2017 Sep 26.

16.

Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients.

Hocker JR, Deb SJ, Li M, Lerner MR, Lightfoot SA, Quillet AA, Hanas RJ, Reinersman M, Thompson JL, Vu NT, Kupiec TC, Brackett DJ, Peyton MD, Dubinett SM, Burkhart HM, Postier RG, Hanas JS.

Cancer Invest. 2017 Oct 21;35(9):573-585. doi: 10.1080/07357907.2017.1373120. Epub 2017 Sep 26.

PMID:
28949774
17.

Use of a Novel Polymer in an Animal Model of Head and Neck Squamous Cell Carcinoma.

Pellionisz PA, Lin Y, Mallen-St Clair J, Luo J, Suwarnasarn A, Schaue D, Elashoff DA, Palma-Diaz F, Dubinett SM, Sharma S, Wu B, St John MA.

Otolaryngol Head Neck Surg. 2018 Jan;158(1):110-117. doi: 10.1177/0194599817730304. Epub 2017 Sep 12.

PMID:
28895464
18.

Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties.

Pagano PC, Tran LM, Bendris N, O'Byrne S, Tse HT, Sharma S, Hoech JW, Park SJ, Liclican EL, Jing Z, Li R, Krysan K, Paul MK, Fontebasso Y, Larsen JE, Hakimi S, Seki A, Fishbein MC, Gimzewski JK, Carlo DD, Minna JD, Walser TC, Dubinett SM.

Cancer Prev Res (Phila). 2017 Sep;10(9):514-524. doi: 10.1158/1940-6207.CAPR-16-0335. Epub 2017 Jul 28.

19.

Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.

Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM.

Clin Cancer Res. 2017 Aug 15;23(16):4556-4568. doi: 10.1158/1078-0432.CCR-16-2821. Epub 2017 May 3.

20.

CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA.

Kang S, Li Q, Chen Q, Zhou Y, Park S, Lee G, Grimes B, Krysan K, Yu M, Wang W, Alber F, Sun F, Dubinett SM, Li W, Zhou XJ.

Genome Biol. 2017 Mar 24;18(1):53. doi: 10.1186/s13059-017-1191-5.

21.

Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.

Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB.

Cell Rep. 2017 Jan 17;18(3):601-610. doi: 10.1016/j.celrep.2016.12.061.

22.

Lung Cancer: Evolving Concepts in Management.

Arenberg D, Dubinett SM.

Semin Respir Crit Care Med. 2016 Oct;37(5):647-648. Epub 2016 Oct 12. No abstract available.

PMID:
27732986
23.

p38 MAPK mediates epithelial-mesenchymal transition by regulating p38IP and Snail in head and neck squamous cell carcinoma.

Lin Y, Mallen-St Clair J, Wang G, Luo J, Palma-Diaz F, Lai C, Elashoff DA, Sharma S, Dubinett SM, St John M.

Oral Oncol. 2016 Sep;60:81-9. doi: 10.1016/j.oraloncology.2016.06.010. Epub 2016 Jul 15.

PMID:
27531877
24.

MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.

Hong CS, Graham NA, Gu W, Espindola Camacho C, Mah V, Maresh EL, Alavi M, Bagryanova L, Krotee PAL, Gardner BK, Behbahan IS, Horvath S, Chia D, Mellinghoff IK, Hurvitz SA, Dubinett SM, Critchlow SE, Kurdistani SK, Goodglick L, Braas D, Graeber TG, Christofk HR.

Cell Rep. 2016 Feb 23;14(7):1590-1601. doi: 10.1016/j.celrep.2016.01.057. Epub 2016 Feb 11.

25.

Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.

Momcilovic M, McMickle R, Abt E, Seki A, Simko SA, Magyar C, Stout DB, Fishbein MC, Walser TC, Dubinett SM, Shackelford DB.

Cancer Res. 2015 Nov 15;75(22):4910-22. doi: 10.1158/0008-5472.CAN-15-0797.

26.

Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway.

Lee MH, Kachroo P, Pagano PC, Yanagawa J, Wang G, Walser TC, Krysan K, Sharma S, John MS, Dubinett SM, Lee JM.

J Cancer Sci Ther. 2014 Nov;6(11):468-477. Epub 2014 Nov 15.

27.

Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.

Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, Milne GL, Figlin RA, Fishbein MC, Elashoff RM, Dubinett SM.

Cancer. 2015 Sep 15;121(18):3298-306. doi: 10.1002/cncr.29480. Epub 2015 May 29.

28.

Drug Development for Metastasis Prevention.

Fontebasso Y, Dubinett SM.

Crit Rev Oncog. 2015;20(5-6):449-73. doi: 10.1615/CritRevOncog.v20.i5-6.150. Review.

29.

Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy.

Liclican EL, Walser TC, Hazra S, Krysan K, Park SJ, Pagano PC, Gardner BK, Larsen JE, Minna JD, Dubinett SM.

Cancer Prev Res (Phila). 2014 Aug;7(8):845-55. doi: 10.1158/1940-6207.CAPR-14-0063. Epub 2014 Jun 9.

30.

A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model.

Lin Y, Luo J, Zhu WE, Srivastava M, Schaue D, Elashoff DA, Dubinett SM, Sharma S, Wu B, St John MA.

Otolaryngol Head Neck Surg. 2014 Sep;151(3):447-53. doi: 10.1177/0194599814533775. Epub 2014 May 13.

31.

Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis.

Ooi AT, Gower AC, Zhang KX, Vick JL, Hong L, Nagao B, Wallace WD, Elashoff DA, Walser TC, Dubinett SM, Pellegrini M, Lenburg ME, Spira A, Gomperts BN.

Cancer Prev Res (Phila). 2014 May;7(5):487-95. doi: 10.1158/1940-6207.CAPR-13-0372. Epub 2014 Mar 11.

32.

Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.

Hanas JS, Peyton MD, Lerner MR, Lightfoot SA, Deb SJ, Hanas RJ, Vu NT, Kupiec TC, Stowell DE, Brackett DJ, Dubinett SM, Hocker JR.

Cancer Invest. 2014 May;32(4):136-43. doi: 10.3109/07357907.2014.883528. Epub 2014 Feb 28.

PMID:
24579933
33.

PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.

Krysan K, Kusko R, Grogan T, O'Hearn J, Reckamp KL, Walser TC, Garon EB, Lenburg ME, Sharma S, Spira AE, Elashoff D, Dubinett SM.

Mol Cancer Res. 2014 May;12(5):765-74. doi: 10.1158/1541-7786.MCR-13-0377. Epub 2014 Jan 27.

34.

Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer.

Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, Hong CS, Kamranpour N, Pitts S, Kabbinavar F, Patel C, von Euw E, Black A, Michelakis ED, Dubinett SM, Slamon DJ.

J Cancer Res Clin Oncol. 2014 Mar;140(3):443-52. doi: 10.1007/s00432-014-1583-9. Epub 2014 Jan 18.

35.

IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer.

Kachroo P, Lee MH, Zhang L, Baratelli F, Lee G, Srivastava MK, Wang G, Walser TC, Krysan K, Sharma S, Dubinett SM, Lee JM.

J Exp Clin Cancer Res. 2013 Nov 25;32:97. doi: 10.1186/1756-9966-32-97.

36.

A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis.

Grant JL, Fishbein MC, Hong LS, Krysan K, Minna JD, Shay JW, Walser TC, Dubinett SM.

Cancer Prev Res (Phila). 2014 Jan;7(1):150-60. doi: 10.1158/1940-6207.CAPR-13-0263. Epub 2013 Nov 19.

37.

MicroRNA 4423 is a primate-specific regulator of airway epithelial cell differentiation and lung carcinogenesis.

Perdomo C, Campbell JD, Gerrein J, Tellez CS, Garrison CB, Walser TC, Drizik E, Si H, Gower AC, Vick J, Anderlind C, Jackson GR, Mankus C, Schembri F, O'Hara C, Gomperts BN, Dubinett SM, Hayden P, Belinsky SA, Lenburg ME, Spira A.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18946-51. doi: 10.1073/pnas.1220319110. Epub 2013 Oct 24.

38.

Models of interinstitutional partnerships between research intensive universities and minority serving institutions (MSI) across the Clinical Translational Science Award (CTSA) consortium.

Ofili EO, Fair A, Norris K, Verbalis JG, Poland R, Bernard G, Stephens DS, Dubinett SM, Imperato-McGinley J, Dottin RP, Pulley J, West A, Brown A, Mellman TA.

Clin Transl Sci. 2013 Dec;6(6):435-43. doi: 10.1111/cts.12118. Epub 2013 Oct 3.

39.

Challenge and opportunity of targeted lung cancer chemoprevention.

Dubinett SM, Spira A.

J Clin Oncol. 2013 Nov 20;31(33):4169-71. doi: 10.1200/JCO.2013.51.2400. Epub 2013 Sep 3. No abstract available.

PMID:
24002497
40.

Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer.

Krysan K, Cui X, Gardner BK, Reckamp KL, Wang X, Hong L, Walser TC, Rodriguez NL, Pagano PC, Garon EB, Brothers JF 2nd, Elashoff D, Lee JM, Spira AE, Sharma S, Fishbein MC, Dubinett SM.

Am J Transl Res. 2013 Aug 15;5(5):481-96. eCollection 2013.

41.

Characteristics of lung cancers harboring NRAS mutations.

Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA Jr, Pao W.

Clin Cancer Res. 2013 May 1;19(9):2584-91. doi: 10.1158/1078-0432.CCR-12-3173. Epub 2013 Mar 20.

42.

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.

Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Jensen MR, Quadt C, Liu M, Dubinett SM, Slamon DJ.

Mol Cancer Ther. 2013 Jun;12(6):890-900. doi: 10.1158/1535-7163.MCT-12-0998. Epub 2013 Mar 14.

43.

Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.

Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett SM, Slamon DJ.

J Thorac Oncol. 2013 Mar;8(3):270-8. doi: 10.1097/JTO.0b013e31827d525c.

44.

Enriching the molecular definition of the airway "field of cancerization:" establishing new paradigms for the patient at risk for lung cancer.

Gomperts BN, Walser TC, Spira A, Dubinett SM.

Cancer Prev Res (Phila). 2013 Jan;6(1):4-7. doi: 10.1158/1940-6207.CAPR-12-0470. Epub 2012 Dec 11.

45.

Green tea inhibits cycolooxygenase-2 in non-small cell lung cancer cells through the induction of Annexin-1.

Lu QY, Jin Y, Mao JT, Zhang ZF, Heber D, Dubinett SM, Rao J.

Biochem Biophys Res Commun. 2012 Nov 2;427(4):725-30. doi: 10.1016/j.bbrc.2012.09.125. Epub 2012 Oct 2.

46.

Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.

St John MA, Wang G, Luo J, Dohadwala M, Hu D, Lin Y, Dennis M, Lee JM, Elashoff D, Lawhon T, Zaknoen SL, Burrows FJ, Dubinett SM.

Br J Cancer. 2012 Aug 7;107(4):707-12. doi: 10.1038/bjc.2012.203. Epub 2012 Jul 24.

47.

Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells.

Dennis M, Wang G, Luo J, Lin Y, Dohadwala M, Abemayor E, Elashoff DA, Sharma S, Dubinett SM, St John MA.

Otolaryngol Head Neck Surg. 2012 Oct;147(4):726-32. Epub 2012 May 7.

48.

A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model.

Hu D, Lau OD, Wang L, Wang G, Schaue D, Zhu L, Huang M, Lin Y, Dennis M, Abemayor E, Elashoff DA, Dubinett SM, McBride WH, Sharma S, Wu B, St John MA.

Arch Otolaryngol Head Neck Surg. 2012 Apr;138(4):412-7. doi: 10.1001/archoto.2012.20.

49.

Na,K-ATPase is a target of cigarette smoke and reduced expression predicts poor patient outcome of smokers with lung cancer.

Huynh TP, Mah V, Sampson VB, Chia D, Fishbein MC, Horvath S, Alavi M, Wu DC, Harper J, Sarafian T, Dubinett SM, Langhans SA, Goodglick L, Rajasekaran AK.

Am J Physiol Lung Cell Mol Physiol. 2012 Jun 1;302(11):L1150-8. doi: 10.1152/ajplung.00384.2010. Epub 2012 Feb 17.

50.

Mitotic inhibitors.

Garon EB, Dubinett SM.

J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1791-2. doi: 10.1097/01.JTO.0000407560.61287.3f. No abstract available.

Supplemental Content

Loading ...
Support Center